Multiple sclerosis is a chronic, long-term disease of the CNS (brain and spinal cord) of unknown etiology which is classified among auto-immune diseases. Sclerotic foci – plaques – cause an inflammation around the nerve fibers, which lose their myelin covers. The nerve impulses are conducted through the fibers at a slower rate or they don’t pass at all. Traditional therapy involves treatment with high doses of corticoids (prednisone, methylprednisolone), while immunomodulation treatment reduces the rate of progression of the disease (interferon beta – 1b, 1a, glatiramer acetate). Treatment with corticoids, however, has side effects (swellings, weight gain, ste-roid acne and psychotic symptoms). Immunomodulation treatment has the following side effects: depression, emotional instability, suicidal tendencies, anxiety and deper¬sonalization. However, treatment fails to bring expected effects for the majority of patients. Amino acid compounds act directly on the cause of the disease. The properties of amino acid compounds enable normalization of the myelin structures. The number of sclerotic foci (plaques) is reduced, thus limiting the progression of the disease. This leads to a relief from symptoms – increased mobility of patients, improved coordination of movements, improved gait, increased muscle strength, and improved vision. With this complicated disorder, we cannot expect a guaranteed effect, but we can expect a positive effect in almost all cases.